C Maurer1, I König2, A Berlis1, W Weber2, S Fischer3. 1. Klinikum Augsburg (C.M., A.B.), Klinik für Diagnostische Radiologie und Neuroradiologie, Ausburg, Germany. 2. From the Knappschaftskrankenhaus Bochum-Langendreer (I.K., W.W., S.F.), Universitätsklinik, Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie, Nuklearmedizin, Bochum, Germany. 3. From the Knappschaftskrankenhaus Bochum-Langendreer (I.K., W.W., S.F.), Universitätsklinik, Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie, Nuklearmedizin, Bochum, Germany sebif101@googlemail.com.
Abstract
BACKGROUND AND PURPOSE: The Woven EndoBridge device proved its effectiveness in the treatment of ruptured and unruptured intracranial aneurysms as a stand-alone device. Before 2016, Woven EndoBridge deployment required at least a 0.021-inch microcatheter. In 2016, a smaller device, the Woven EndoBridge 17 with finer size increments that used a 0.017-inch microcatheter, was introduced. We retrospectively analyzed our initial and follow-up results with the Woven EndoBridge 17 in ruptured and unruptured aneurysms. MATERIALS AND METHODS: One hundred twenty-seven intracranial aneurysms in 117 patients were scheduled for treatment with the Woven EndoBridge 17 between June 2017 and February 2019. Twenty-nine aneurysms were ruptured. RESULTS: Treatment was performed as intended in 124 of 127 cases (97.6%). Additional devices such as stents or coils were used in 12 cases (9.7%). Five thromboembolic complications and 1 hemorrhagic complication were encountered, resulting in clinical deterioration in 2 patients. The overall morbidity and mortality in the entire series have been 1.7% and 0.0% to date, respectively. The follow-up results at 3 and 12 months revealed complete occlusion in 76.1% (70/92) and 78.0% (32/41). CONCLUSIONS: The Woven EndoBridge 17 device is safe in the treatment of small broad-based aneurysms without the general need for additional devices. The low complication rate and the promising follow-up results underline the value of this technique in a growing range of endovascular treatment options for intracranial aneurysms.
BACKGROUND AND PURPOSE: The Woven EndoBridge device proved its effectiveness in the treatment of ruptured and unruptured intracranial aneurysms as a stand-alone device. Before 2016, Woven EndoBridge deployment required at least a 0.021-inch microcatheter. In 2016, a smaller device, the Woven EndoBridge 17 with finer size increments that used a 0.017-inch microcatheter, was introduced. We retrospectively analyzed our initial and follow-up results with the Woven EndoBridge 17 in ruptured and unruptured aneurysms. MATERIALS AND METHODS: One hundred twenty-seven intracranial aneurysms in 117 patients were scheduled for treatment with the Woven EndoBridge 17 between June 2017 and February 2019. Twenty-nine aneurysms were ruptured. RESULTS: Treatment was performed as intended in 124 of 127 cases (97.6%). Additional devices such as stents or coils were used in 12 cases (9.7%). Five thromboembolic complications and 1 hemorrhagic complication were encountered, resulting in clinical deterioration in 2 patients. The overall morbidity and mortality in the entire series have been 1.7% and 0.0% to date, respectively. The follow-up results at 3 and 12 months revealed complete occlusion in 76.1% (70/92) and 78.0% (32/41). CONCLUSIONS: The Woven EndoBridge 17 device is safe in the treatment of small broad-based aneurysms without the general need for additional devices. The low complication rate and the promising follow-up results underline the value of this technique in a growing range of endovascular treatment options for intracranial aneurysms.
Authors: David Fiorella; Andrew Molyneux; Alexander Coon; Istvan Szikora; Isil Saatci; Feyyaz Baltacioglu; Ali Sultan; Adam Arthur Journal: J Neurointerv Surg Date: 2017-01-17 Impact factor: 5.836
Authors: Laurent Pierot; Vincent Costalat; Jacques Moret; Istvan Szikora; Joachim Klisch; Denis Herbreteau; Markus Holtmannspötter; Werner Weber; Anne-Christine Januel; Thomas Liebig; Vojtech Sychra; Christoph Strasilla; Christophe Cognard; Alain Bonafé; Andrew Molyneux; James V Byrne; Laurent Spelle Journal: J Neurosurg Date: 2015-09-18 Impact factor: 5.115
Authors: Adam S Arthur; Andy Molyneux; Alexander L Coon; Isil Saatci; Istvan Szikora; Feyyaz Baltacioglu; Ali Sultan; Daniel Hoit; Josser E Delgado Almandoz; Lucas Elijovich; Saru Cekirge; James V Byrne; David Fiorella Journal: J Neurointerv Surg Date: 2019-04-16 Impact factor: 5.836
Authors: Sbt van Rooij; M E Sprengers; J P Peluso; J Daams; D Verbaan; W J van Rooij; C B Majoie Journal: Interv Neuroradiol Date: 2020-02-06 Impact factor: 1.610
Authors: Jessica K Campos; Barry Cheaney Ii; Brian V Lien; David A Zarrin; Chau D Vo; Geoffrey P Colby; Li-Mei Lin; Alexander L Coon Journal: Stroke Vasc Neurol Date: 2020-03-25